Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists

European Journal of Heart Failure

Volumn 4, Issue 1, 2002, Pages 73-82

  Persson, Hans ^a   Andréasson, Karin ^a   Kahan, Thomas ^a   Eriksson, Sven V ^a   Tidgren, Bo ^a   Hjemdahl, Paul ^b   Hall, Christian ^c   Erhardt, Leif ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF OSLO   (Norway)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Atrial natriuretic peptide; Beta adrenergic blocking agents; Cardiac function; Congestive heart failure; Myocardial infarction; Neurohormonal activation

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE DERIVATIVE; DOPAMINE; FUROSEMIDE; METOPROLOL; NEUROPEPTIDE Y; NORADRENALIN; RENIN; XAMOTEROL;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HORMONAL REGULATION; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; CHI-SQUARE DISTRIBUTION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER; EPINEPHRINE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL INFARCTION; NEUROPEPTIDE Y; NOREPINEPHRINE; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; XAMOTEROL;

EID: 0036154656     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(01)00196-9     Document Type: Article

References (43)

1. Activation of neurohormonal systems following acute myocardial infarction
2. Neuroendocrine activation after acute myocardial infarction
3. How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines
4. Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: Effect of captopril
5. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
6. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure
7. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Effect of metoprolol CR/XL in chronic heart failure
8. The effect of carvedilol on survival and hospitalization for cardiovascular complications in patients with chronic heart failure
9. Neurohormonal variability in left ventricular dysfunction
10. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction
11. Effects of beta-receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: Double blind comparison of metoprolol and xamoterol
12. Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection
13. Accurate and rapid measurement of plasma renin activity by radioimmunoassay. Results in normal and hypertensive people
14. Radio-immunoassay for neuropeptide Y (NPY): Chromatographic characterization of immunoreactivity in plasma and tissue extracts
15. Identification and plasma concentrations of the N-terminal fragment of pro-atrial natriuretic factor in man
16. Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction
17. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
18. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relationship to mortality
19. Plasma atrial natriuretic peptide is related to systolic but not diastolic myocardial function
20. N-Terminal proatrial natriuretic peptide and left ventricular filling pattern in patients with idiopathic dilated cardiomyopathy
21. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure
22. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure
23. Short and long term neurohormonal activation following acute myocardial infarction
24. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction
25. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure
26. Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan
27. Plasma catecholamine levels in acute myocardial infarction: Influence of beta-adrenergic blockade and relation to central hemodynamics
28. Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure
29. Neuroendocrine changes post myocardial infarction: Effects of xamoterol
30. Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction
31. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man
32. Influence of sympathetic discharge pattern on norepinephrine and neuropeptide Y release
33. Splanchnic and renal vasoconstrictor and metabolic responses to neuropeptide Y in resting and exercising man
34. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake
35. Effects of propranolol and pindolol on plasma lignocaine clearance in man
36. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure
37. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern
38. 2+ infusion, and aortic constriction in pigs
39. Short-term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension
40. Effects of propranolol and pindolol on plasma ANP levels in humans at rest and during exercise
41. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: A double blind, randomized comparison of metoprolol and a third generation vasodilating beta blocker
42. Plasma proatrial natriuretic factor (1-98) concentration after myocardial infarction: Relation to indices of cardiac and renal function
43. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy